Trastuzumab deruxtecan (T-DXd) vs physician's choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06)

被引：42

作者：

Curigliano, Giuseppe ^{[1
,2
]}

Hu, Xichun ^{[3
]}

Dent, Rebecca Alexandra ^{[4
]}

Yonemori, Kan ^{[5
]}

Barrios Sr, Carlos H. ^{[6
]}

O'Shaughnessy, Joyce ^{[7
]}

Wildiers, Hans ^{[8
]}

Zhang, Qingyuan ^{[9
]}

Im, Seock-Ah ^{[10
]}

Saura, Cristina ^{[11
]}

Biganzoli, Laura ^{[12
]}

Sohn, Joohyuk ^{[13
]}

Levy, Christelle ^{[14
]}

Jacot, William ^{[15
]}

Begbie, Natasha ^{[16
]}

Ke, Jun ^{[17
]}

Patel, Gargi Surendra ^{[18
]}

Bardia, Aditya

机构：

[1] Univ Milan, Milan, Italy

[2] IRCCS, European Inst Oncol, Milan, Italy

[3] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China

[4] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[5] Natl Canc Ctr, Tokyo, Japan

[6] Latin Amer Cooperat Oncol Grp LACOG, Porto Alegre, Brazil

[7] Baylor Univ, US Oncol Network, Texas Oncol, Med Ctr, Dallas, TX USA

[8] Univ Hosp Leuven, Dept Gen Med Oncol, Leuven, Belgium

[9] Harbin Med Univ Canc Hosp, Harbin, Peoples R China

[10] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[11] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain

[12] Santo Stefano Hosp, Azienda USL Toscana Ctr, Dept Oncol, Prato, Italy

[13] Yonsei Canc Ctr, Div Med Oncol, Seoul, South Korea

[14] Ctr Francois Baclesse, Caen, France

[15] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Montpellier, France

[16] AstraZeneca, Clin Dev, Late Stage Dev, Oncol R&D, Cambridge, England

[17] AstraZeneca, Biometr Oncol, Late Stage Dev, Oncol R&D, Waltham, MA USA

[18] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 17_SUPPL期

关键词：

D O I：

10.1200/JCO.2024.42.17_suppl.LBA1000

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA1000

引用

页码：LBA1000 / LBA1000

页数：1

共 50 条

[21] Subgroup analysis by disease history and prior treatments of patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1)
Cortes, J.
Im, S-A.
Iwata, H.
Hamilton, E. P.
Hurvitz, S. A.
Egorov, A.
Cathcart, J.
Liu, Y.
Bako, E.
Curigliano, G.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S645 - S646
[22] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09
Tolaney, S. M.
Barroso-Sousa, R.
Jiang, Z.
Park, Y. H.
Rimawi, M.
Manich, C. Saura
Schneeweiss, A.
Toi, M.
Yu, T.
Shetty, J.
Herbolsheimer, P.
Loibl, S.
ANNALS OF ONCOLOGY, 2021, 32 : S507 - S508
[23] RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM
Campone, Mario
Tripathy, Debu
Chia, Stephen
Diaz-Padilla, Ivan
Lorenc, Karen R.
Miller, Michelle
Germa, Caroline
Conte, Pierfranco
BREAST, 2017, 36 : S50 - S50
[24] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) metastatic breast cancer
Sudpreeda Chainitikun
James P. Long
Ruben Rodriguez-Bautista
Toshiaki Iwase
Debu Tripathy
Takeo Fujii
Naoto T. Ueno
Breast Cancer Research and Treatment, 2020, 183 : 729 - 739
[25] The efficacy of first-line chemotherapy in endocrine-resistant hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer
Chainitikun, Sudpreeda
Long, James P.
Rodriguez-Bautista, Ruben
Iwase, Toshiaki
Tripathy, Debu
Fujii, Takeo
Ueno, Naoto T.
BREAST CANCER RESEARCH AND TREATMENT, 2020, 183 (03) : 729 - 739
[26] Patient-reported outcomes (PROs) from DESTINY-Breast03, a randomized phase III study of trastuzumab deruxtecan (T-DXd) vs trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (MBC)
Curigliano, G.
Dunton, K.
Rosenlund, M.
Janek, M.
Cathcart, J.
Liu, Y.
Fasching, P. A.
Iwata, H.
ANNALS OF ONCOLOGY, 2022, 33 : S196 - S197
[27] Second-line endocrine therapy (ET) with or without palbociclib (P) maintenance in patients (pts) with hormone receptor-positive (HR[ plus ])/human epidermal growth factor receptor 2-negative (HER2[-]) advanced breast cancer (ABC): PALMIRA trial
Llombart-Cussac, Antonio
Harper-Wynne, Catherine
Perello, Antonia
Hennequin, Audrey
Fernandez, Adela
Colleoni, Marco
Caranana, Vicente
Quiroga, Vanesa
Medioni, Jacques
Iranzo, Vega
Wheatley, Duncan
Del Barco, Sonia
Anton, Antonio
Dobi, Erion
Ruiz-Borrego, Manuel
Alcala-Lopez, Daniel
Perez-Escuredo, Jhudit
Sampayo-Cordero, Miguel
Perez-Garcia, Jose Manuel
Cortes, Javier
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[28] Ribociclib plus letrozole in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2) advanced breast cancer (aBC) with no prior endocrine therapy (ET) for ABC: CompLEEment-1 trial, preliminary results from Spanish population
Salvador, J.
Ciruelos, E. M.
Prat, A.
Jimenez-Rodriguez, B.
de la Cruz, L.
Martinez, N.
Villanueva Vazquez, R.
de Toro, R.
Anton, A.
Moreno, F.
Alvarez, I.
Gavila, J.
Quiroga, V.
Vicente, E.
de la Haba, J.
Gonzalez-Santiago, S.
Diaz, N.
Barnadas, A.
Cantos Sanchez de Ibarguen, B.
Delgado, J. I.
Bellet, M.
Gimeno, A.
Sanz, S.
Martin, M.
CANCER RESEARCH, 2019, 79 (04)
[29] Systematic Literature Review of Hormone Receptor (HR) Positive, Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer Patients from India
Singh, M.
Pratiksha, K.
Alam, M.
EUROPEAN JOURNAL OF CANCER, 2015, 51 : S160 - S160
[30] Patients' preferences for postmenopausal hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer treatments in Japan
Omori, Y.
Enatsu, S.
Cai, Z.
Ishiguro, H.
CANCER RESEARCH, 2019, 79 (04)

← 1 2 3 4 5 →